TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Trough tacrolimus blood concentration to dose ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average Cups of Fruit per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Cups of Vegetables per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Minutes of Physical Activity Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Pexidartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) of Pexidartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-Life (t1/2) of Pexidartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient assessment questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Interleukin-6 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diphtheria seroprotection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tetanus seroprotection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Polio seroprotection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pertussis response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in daily hours crying time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amplitude of heart rate response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Corneal Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Bowel Preparation Score (BBPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FA (Fluorescein Angiography)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEP (Visual Evoked Potential)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: OCT (Optical Coherence Tomography)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Worst pain in movement and rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain in movement and rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of clinical criteria according to CGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Objective Response Rate (cORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of arrest for violent and firearm-related crimes
Endpoint domain: Mortality/survival
Primary endpoint: Change in Height for Age Z-scores (HAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (Complete Remission + Partial Remission)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Seltorexant and its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Last Observed Measurable Plasma Concentration (Clast) of Seltorexant and its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Seltorexant and its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Opioid Dose Used for Pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: micro-RNA 146-a expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of micro-RNA 126
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients alive after 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Lack of device related major adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Metabolic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Combined mortality or survival to tertiary hospital discharge without severe morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Combined mortality or survival with neurodevelopmental disability
Endpoint domain: Mortality/survival
Primary endpoint: 16-Week Progression-free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Bates-Jensen Wound Assessment Score - Modified (BWAT-m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HbA1c reduction of at least 1%-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eyeball elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of propofol and remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post Traumatic Checklist-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: knowledge of PTSD scale (KPTSD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Who Show Improvement in the Mucosa at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Who Show Improvement in the Mucosa at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity according to PASDAS categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of variability of the heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Willingness to forgo mammograms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of histologically complete (R0) resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Appendicular Lean Body Mass (aLBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Endothelial Progenitor Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Aldofluor Positive Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severity of allergic eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Performance on tests of sustained attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance on tests of episodic memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance on tests of working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of ventilation weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Experience Any Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of insulin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in eye comfort ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of escalating doses of IL13-PE38QQR
Endpoint domain: Adverse events/effects
Primary endpoint: HPV Vaccine Series Initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Warwick-Edinburgh Mental Well-being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dietary Intake Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: HIV infection of the newborn
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence of Antiretroviral treatment (ART) during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of completed surveys and phone interviews
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ODI questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Platinum levels excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subprophylactic anticoagulation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: migration (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale (HDRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of psychoactive substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Families With Sustained Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain immediately after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Withdrew From the Study Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Ulcer surface measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laxation within four hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response of Anterior Uveitis to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pad Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of biopsy proven acute rejection requiring treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first biopsy proven acute rejection requiring treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: presence of active cerebral microemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: altered perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ischemic brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression-free for at Least 6 Months Without Non-protocol Therapy From Study Entry
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analogue Scale Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Tender Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morcellation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hepatitis B surface antigen (HBsAg) test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Cardboard 9 Hole Peg Test speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological Performance Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Prolonged Hematologic Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional Independence Measure (task 9 shorter transfer and task 13 stairs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on a Depression Severity Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with lymph metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increase in blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of viral events before T1D diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Delay between viral events and T1D diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of significant prostate cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bowel Function Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline in HDL-c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of children who required analgesics
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with at least 30% hair reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Levels of Progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adequate Relief of abdominal pain or discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under Curve (AUC) last
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Progression Free Survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Psychosocial development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in Schirmer Tear Test (STT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BMD (Z score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Death in ICU
Endpoint domain: Mortality/survival
Primary endpoint: Foveal microstructure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Traumatic Stress Disorder (PTSD) symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Albumin/Creatinine Ratio (UACR) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline in neurological assessments - SAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in neurological assessments - BCTQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in neurological assessments - 4th finger test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Best Overall Response (BOR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Geometric mean titer (GMT) of anti-EV71 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safe dose for oral ALA administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal discrimination between normal and malignant tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition to category 3 or lower on WHO scale by Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcome of PA0903 as root canal sealer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic outcome of PA0903 as root canal sealer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of recruiting and enrollment procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of intervention website users
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physician Global Assessment of Psoriasis (PGA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory changes in pulse oximeter plethysmographic amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assay Performance for Detecting CIN2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection Rate of Adenomas and Serrated Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: National Quality Forum Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Consumer Assessment of Healthcare Providers and Systems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to refill
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: retinal oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker levels in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function variables by spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total opioid use at 48 hours postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Modified Disease Activity Score (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensitivity measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain severity measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean logMAR Contact Lens Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Slit Lamp Findings Greater Than Grade 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: World Health Organization Disability Assessment Scale 2.0 Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evaluation of device and/or procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of blood chemistry, hematology and urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Iowa Gambling Task Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Anxiety Rating Scale (HAM-A) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Beck Depression Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of NACE at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of NACE at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of women willing to be vaccinated against pertussis and flu during pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of health professionals agreeing to vaccinate pregnant women against flu and pertussis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects Experiencing Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate-Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infections related to care
Endpoint domain: Adverse events/effects
Primary endpoint: Median Progression-Free Survival (PFS) Time
Endpoint domain: Mortality/survival
Primary endpoint: Blood flow velocity in brachial artery and vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients achieving hormone refractory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hospitalization(s) at 1 month
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: PACU Length of Stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Length of Stay (HLOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU Length of Stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of Myocardial Infarction, Stroke, or Cardiovascular Death
Endpoint domain: Mortality/survival
Primary endpoint: First Occurrence of Major Bleeding
Endpoint domain: Adverse events/effects